Market
Highlights
Pseudotumor
Cerebri, also known as idiopathic intracranial hypertension, is a challenging
condition with a rapidly increasing prevalence due to a close relation to
obesity. Headache is the most common symptom of this condition, a persistent
symptom in around 93% of patients, with pseudotumor cerebri, at the time of
diagnosis.
A
number of factors such as increasing technological advancements, and growing
prevalence of obesity, are propelling the growth of the global pseudotumor
cerebri market. An increased incidence of pseudotumor cerebri, unmet medical
needs, improving regulatory framework, increasing government assistance,
increasing adoption rate of new technology, and improvement in funding and
improved reimbursement policies are also boosting the growth of the market.
However,
cost of treatment, side-effects associated with surgical interventions, and
poor healthcare system in low and middle-income countries may hamper the growth
of the market over the forecast period.
Request
For Sample Report: https://www.marketresearchfuture.com/sample_request/5709
Regional
Analysis
The
Americas dominate the pseudotumor cerebri market owing to the rising occurrence
of pseudotumor cerebri in this region, and technological advancements.
According to the study suggested by International Ophthalmology Clinics in
2014, the annual incidence of idiopathic intracranial hypertension in the
Western world is around 0.9 per 100,000 individuals and 3.5 per 100,000 in
females, in between 15 to 44 years of age. It is also reported that the annual
cost of idiopathic intracranial hypertension in the United States had been
exceeded to USD 444 million due to frequent hospitalizations, and its inclination
in young working-age adults which results in a significant loss of productivity
Europe
holds the second position in the pseudotumor cerebri market. It is found that
the government support towards research & development, and favourable
amendments in the reimbursement policies in the healthcare is likely to drive
the European pseudotumor cerebri market.
Asia
Pacific is the fastest growing pseudotumor cerebri market owing to a huge
patient pool and development in healthcare technology. Healthcare expenditure
is found to be boosting in various regions of Asia Pacific. As per the data
suggested by the Australian Institute of Health and Welfare during the year
2015-16, the total health expenditure was nearly USD 170.4 billion, i.e., 3.6%
higher than the expenditure of 2014-2015.
The
Middle East & Africa holds the lowest share of the global market due to
slow development, lack of technical knowledge, and poor medical facilities.
Access Report Details @ https://www.marketresearchfuture.com/reports/pseudotumor-cerebri-market-5709
Segmentation
The
global pseudotumor cerebri market is segmented on the basis of diagnosis,
treatment, and end user.
By
the diagnosis, the market is classified as fundoscopy, neuroimaging, lumbar
puncture, and others.
On
the basis of the treatment, the market is classified as surgery, medication,
and others. The surgery is further segmented into the spinal fluid shunt, optic
nerve sheath fenestration (ONSF), dural venous sinus stenting, and bariatric
surgery. The medication is further segmented into acetazolamide, topiramate,
furosemide, steroids, others.
By
the end user, the market is segmented into hospitals, clinics, diagnostic
centers, drug stores, pharmacies, and others.
Key
Players
Some of key the players in the global
pseudotumor cerebri market are Avkare, Inc, B. Braun Melsungen AG, Beckersmith
Medical, Inc, Elekta AB, Heritage Pharmaceuticals Inc, Ingenus Pharmaceuticals,
Integra LifeSciences Corporation, Johnson & Johnson Services, Inc., Lannett
Company, Inc., Magstim, Medtronic, MercuryPharma, Nostrum Laboratories Inc,
Novast Holdings Ltd., Phoenix Biomedical Corp., Sanofi, SGPharma Pvt. Ltd.,
Sophysa, Taro Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries
Ltd, West-Ward Pharmaceutical, Zydus Pharmaceuticals, Inc., and others.
No comments:
Post a Comment